Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company’s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
Prognosis for these older AML patients remains very poor, with 5-year survival rates an estimated 3-8%. Given that the median age for AML diagnosis is 65, this is clearly a disease with a high unmet medical need. Prexigebersen, Bio-Path’s AML drug candidate, blocks the production of Grb2, a protein on cancer cells that induces cell growth and proliferation. Inactivation of Grb2 has been shown to halt cancer cell proliferation and enhance the anticancer activity of chemotherapeutic agents. To learn more about prexigebersen and Bio-Path’s other pipeline candidates, please click here.What is DNAbilize™
Bio-Path was founded with technology licensed from The University of Texas MD Anderson Cancer Center and maintains a strong working relationship with the Cancer Center. Intellectual property includes composition of matter and method patents for liposomal antisense DNA targets and manufacturing that enables systemic delivery of antisense drugs through a patient’s vascular system.
Bio-Path Holdings is actively developing new targets for hematopoietic diseases and solid tumors and collaborates with academic and clinical leaders to build programs in and beyond oncology.